miR-9 regulation of BRCA1 and ovarian cancer sensitivity to cisplatin and PARP inhibition. - Wikidata - wikimedia - TriplyDB

miR-9 regulation of BRCA1 and ovarian cancer sensitivity to cisplatin and PARP inhibition.

miR-9 regulation of BRCA1 and ovarian cancer sensitivity to cisplatin and PARP inhibition.

http://www.wikidata.org/entity/Q34380980

about

Impact of Nutrition on Non-Coding RNA Epigenetics in Breast and Gynecological Cancer MicroRNAs, DNA Damage Response, and Cancer Treatment Prognostic role of miR-9 expression in various human malignant neoplasms: a meta-analysis MicroRNAs Used in Combination with Anti-Cancer Treatments Can Enhance Therapy Efficacy "Back to a false normality": new intriguing mechanisms of resistance to PARP inhibitors Low concentration of quercetin antagonizes the cytotoxic effects of anti-neoplastic drugs in ovarian cancer.The BRCA1/2-directed miRNA signature predicts a good prognosis in ovarian cancer patients with wild-type BRCA1/2.TGFβ induces "BRCAness" and sensitivity to PARP inhibition in breast cancer by regulating DNA-repair genes DNA damage response markers are differentially expressed in BRCA-mutated breast cancers miR-205 acts as a tumour radiosensitizer by targeting ZEB1 and Ubc13.Depletion of eIF2·GTP·Met-tRNAi translation initiation complex up-regulates BRCA1 expression in vitro and in vivo.Sarcoma Cell Line Screen of Oncology Drugs and Investigational Agents Identifies Patterns Associated with Gene and microRNA Expression Mitochondrial fission determines cisplatin sensitivity in tongue squamous cell carcinoma through the BRCA1-miR-593-5p-MFF axis.miR-9 Acts as an OncomiR in Prostate Cancer through Multiple Pathways That Drive Tumour Progression and Metastasis.Prognostic value of microRNA-9 in cancers: a systematic review and meta-analysis.MicroRNA Gene Expression Signature Driven by miR-9 Overexpression in Ovarian Clear Cell Carcinoma.Micro-RNAs associated with the evolution of ovarian cancer cisplatin resistance.A chemotherapy response classifier based on support vector machines for high-grade serous ovarian carcinoma Effect of the BRCA1-SIRT1-EGFR axis on cisplatin sensitivity in ovarian cancer.MicroRNA deregulation in triple negative breast cancer reveals a role of miR-498 in regulating BRCA1 expression.Regulation of multidrug resistance by microRNAs in anti-cancer therapy MiR-199a-5p and let-7c cooperatively inhibit migration and invasion by targeting MAP4K3 in hepatocellular carcinoma Let-7e sensitizes epithelial ovarian cancer to cisplatin through repressing DNA double strand break repair.Epigenetic perspectives on cancer chemotherapy response.Ovarian cancer: diagnostic, biological and prognostic aspects.miRNAs as prognostic and therapeutic tools in epithelial ovarian cancer.MicroRNA in Ovarian Biology and Disease.miRNAs and ovarian cancer: a miRiad of mechanisms to induce cisplatin drug resistance.Targeting mitotic pathways for endocrine-related cancer therapeutics.MicroRNAs and cancer resistance: A new molecular plot.Recently identified drug resistance biomarkers in ovarian cancer.miR-9 promotes cell proliferation and inhibits apoptosis by targeting LASS2 in bladder cancer.The role of exosomes and miRNAs in drug-resistance of cancer cells.MicroRNA-mediated drug resistance in ovarian cancer.Propofol inhibits invasion and growth of ovarian cancer cells via regulating miR-9/NF-κB signal.Plasma microRNA-9 as a diagnostic and prognostic biomarker in patients with esophageal squamous cell carcinoma The potential role of miRNAs in therapy of breast and ovarian cancers associated with BRCA1 mutation.Overexpressed miR-9 promotes tumor metastasis via targeting E-cadherin in serous ovarian cancer.The Double Face of Exosome-Carried MicroRNAs in Cancer Immunomodulation.C/EBPβ enhances platinum resistance of ovarian cancer cells by reprogramming H3K79 methylation.

P2860

Q27016123-B240A178-6A0E-4AAD-A388-F7798930B84A Q28067062-41A114F3-1EB9-40A4-A421-0335CED4C982 Q28079614-8D36DB46-3E68-4A34-BF76-B1CBB15C2EF1 Q28829013-1A84539D-1F7E-47FD-8C64-0E12C86140D0 Q33618910-458CE5F1-617B-4F5F-993C-9684E88228CF Q33856711-FBE00E26-8C62-4E57-B463-0D7FAE525378 Q34455481-1274EB07-9433-4397-841B-C011C11A4A66 Q34518332-716B51B1-B604-48A2-A359-9C59EEDBA129 Q35131267-D7D96B63-CC7B-464C-83E8-AA078BEF098E Q35225778-4C11BCF4-7A62-449D-9201-3B430AFA7596 Q35740103-AD56CBB7-7749-4C35-B33C-C6E98992F734 Q35767389-340003DC-193F-4066-B97C-D836B370BC70 Q36020872-973A7F14-6691-421E-978D-68C2A3B36DCC Q36083567-275163B9-055F-42D3-BD2E-B9063C7B0F08 Q36114010-5F22C6F2-EC4E-406A-BFF7-B8F61A8D291F Q36128575-7E570D6E-6A50-4A09-B6AD-AFB8BCD2E8F2 Q36494718-7157F0EA-14DA-466B-ADB6-D64DE75E6620 Q36772106-3CDD4B2D-1232-4B46-8B8B-E986B53EA701 Q36878642-676CE1AB-2391-4732-A5F7-D7803399F69A Q37190254-34878B36-4D57-427E-8647-7708E51DE8F1 Q37587311-F9A7E9F9-39CB-4594-9B52-3C5F414B64D8 Q37706681-75B75D1B-41B7-4FD7-A8F1-26BB2B660A08 Q37736667-F48F0727-56D2-4867-9C80-72EA5F109F22 Q38209574-F5C90833-CB38-4FE8-93EE-F4A4A9FF9C46 Q38261795-938AD9F1-BB40-4BC4-B20A-3F15376161D4 Q38366731-AB4D6E09-81ED-4CE5-8AC1-4B508810D1A8 Q38489481-FB2CDF8F-4134-4368-BDD3-A2A6475C9A3A Q38633144-05301638-707E-4E70-9669-9992D098E172 Q38671036-BF53C9DF-6B8E-4AEB-B13D-41E11B1346FA Q38732712-B871BD34-142D-49C3-BCB9-318752E31849 Q38741073-1F606D5D-139B-4060-8059-CD83C6472D03 Q38856001-575006C7-ED03-43B0-9AA5-1C1C053E1DDB Q39152624-B3A48FA2-7757-4CB6-87E3-7F194B568DDE Q39382756-C248613B-FDCC-4564-A2FC-C9ECFDA94D8E Q39959213-0CDAD68C-370B-4B53-B722-906A1E084337 Q41848455-C3C8F05E-EC4B-42C1-BFB0-2809552F459A Q42368096-D2611E50-B2D3-4EC5-A8A6-4272C1D48367 Q51021300-EF785524-C291-473E-8BE4-382A6E166846 Q52589944-760341A4-DD61-4163-8AF0-2A2647516ADE Q53689778-1BC14087-BD26-4644-8157-75ECB020D472

P2860

miR-9 regulation of BRCA1 and ovarian cancer sensitivity to cisplatin and PARP inhibition.

http://www.wikidata.org/entity/Q34380980

description

2013 nî lūn-bûn

@nan

2013 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

miR-9 regulation of BRCA1 and ...... cisplatin and PARP inhibition.

@ast

miR-9 regulation of BRCA1 and ...... cisplatin and PARP inhibition.

@en

miR-9 regulation of BRCA1 and ...... cisplatin and PARP inhibition.

@nl

type

label

miR-9 regulation of BRCA1 and ...... cisplatin and PARP inhibition.

@ast

miR-9 regulation of BRCA1 and ...... cisplatin and PARP inhibition.

@en

miR-9 regulation of BRCA1 and ...... cisplatin and PARP inhibition.

@nl

prefLabel

miR-9 regulation of BRCA1 and ...... cisplatin and PARP inhibition.

@ast

miR-9 regulation of BRCA1 and ...... cisplatin and PARP inhibition.

@en

miR-9 regulation of BRCA1 and ...... cisplatin and PARP inhibition.

@nl

P1433

Q34380980-5AA45ACC-BE83-4517-8685-F78918C66723

P1476

Q34380980-4F623F37-272D-4A54-9533-B5E24C4287CC

P2093

Q34380980-373FD181-219B-45AF-A38E-A62346F9D45F

Q34380980-41DFCD2D-2317-4292-BACB-7AF9C6717DAF

Q34380980-42B6A0C5-69BA-4116-B05F-1F27BF43391C

Q34380980-455DA5C4-61D1-4480-B8FC-8C5AE2154817

Q34380980-5270E50B-7E93-4DAF-BFFB-F1ADBB226B26

Q34380980-5673B140-C3D4-45FE-90B7-BF133BC0714F

Q34380980-699A2AFD-E33F-4DB6-BD7A-3C5F0D011A70

Q34380980-69B0CB47-25E6-44AE-B29F-6DC10A97AD0B

Q34380980-93C3681E-94C5-4785-9B0E-C7F9D44D3694

Q34380980-A0478340-1774-4619-99DB-C054A4CB62B3

P2860

Q34380980-0417E821-810C-4468-9F1A-5BFC7EB4C89E

Q34380980-043DED0D-C8EB-436C-938F-0FE2C90C9614

Q34380980-06958315-5F72-431C-A745-B3522DF50F31

Q34380980-0B6BE12E-C367-4176-9953-C106403E614D

Q34380980-10A35D80-E655-4A90-8FE0-AAA6D47A770B

Q34380980-2114CA78-777C-4A64-88CF-5063B82C6079

Q34380980-23B80C88-9467-4B01-962D-DED8170B3753

Q34380980-27362180-BAE9-4EDD-8F74-6547704BEF0D

Q34380980-2C72C07F-C648-4F9F-B7CC-2400921943B0

Q34380980-30B6E0A7-A9EB-421C-8E95-E7BA33DB104A

P304

Q34380980-214274D9-79FD-40D0-A810-821EB269A8EF

P31

Q34380980-C4B71EF4-EBD8-47F8-9883-ED8B60AA7099

P356

Q34380980-C51C9E03-141F-4AB9-835B-BD575E5EACE7

P407

Q34380980-336715F0-307B-45CC-AF36-089C95509677

P433

Q34380980-63A3DE91-2D74-4C59-AA3D-2AE3D5F24748

P478

Q34380980-8AAF2A15-B41A-4CDC-8315-F41313E7512B

P577

Q34380980-96AD3D8D-67C6-4E88-B4E1-4772C1E5EB0A

P698

Q34380980-BAF141D6-5F9C-4500-9D5D-DE2433FE06B7

P921

Q34380980-518F1B9B-B903-4AF5-A371-DA198578DDF5

P356

P1433

Journal of the National Cancer Institute

P1476

miR-9 regulation of BRCA1 and ...... cisplatin and PARP inhibition.

@en

P2093

Bo Zhou

http://www.w3.org/2001/XMLSchema#string

Chaoyang Sun

http://www.w3.org/2001/XMLSchema#string

Danhui Weng

http://www.w3.org/2001/XMLSchema#string

Ding Ma

http://www.w3.org/2001/XMLSchema#string

Gang Chen

http://www.w3.org/2001/XMLSchema#string

Jianfeng Zhou

http://www.w3.org/2001/XMLSchema#string

Na Li

http://www.w3.org/2001/XMLSchema#string

Peng Wu

http://www.w3.org/2001/XMLSchema#string

Pingbo Chen

http://www.w3.org/2001/XMLSchema#string

Xiaokui Yang

http://www.w3.org/2001/XMLSchema#string

P2860

Potential role of miR-9 and miR-223 in recurrent ovarian cancer

Global cancer statistics

Abraxas and RAP80 form a BRCA1 protein complex required for the DNA damage response

MiR-92b and miR-9/9* are specifically expressed in brain primary tumors and can be used to differentiate primary from metastatic brain tumors

Most mammalian mRNAs are conserved targets of microRNAs

Regulation of the p27(Kip1) tumor suppressor by miR-221 and miR-222 promotes cancer cell proliferation

Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers.

BRCA1 is both a prognostic and predictive biomarker of response to chemotherapy in sporadic epithelial ovarian cancer.

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

MicroRNA regulation of DNA repair gene expression in hypoxic stress

P304

1750-1758

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/JNCI/DJT302

http://www.w3.org/2001/XMLSchema#string

P407

P433

22

http://www.w3.org/2001/XMLSchema#string

P478

105

http://www.w3.org/2001/XMLSchema#string

P577

2013-10-29T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24168967

http://www.w3.org/2001/XMLSchema#string

P921